Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.00)
# 2,986
Out of 4,905 analysts
56
Total ratings
30%
Success rate
-0.86%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Assumes: Buy | $9 | $3.82 | +135.60% | 2 | Jul 16, 2025 | |
| ANIP ANI Pharmaceuticals | Initiates: Buy | $84 | $67.75 | +23.99% | 4 | Jul 10, 2025 | |
| ZVRA Zevra Therapeutics | Initiates: Buy | $26 | $12.44 | +109.00% | 1 | Jul 2, 2025 | |
| CRMD CorMedix | Initiates: Buy | $20 | $11.00 | +81.82% | 2 | Jun 30, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $12 | $5.41 | +121.83% | 2 | Jun 26, 2025 | |
| CNTB Connect Biopharma Holdings | Assumes: Buy | $7 | $1.76 | +297.70% | 1 | Jun 12, 2025 | |
| PYPD PolyPid | Maintains: Buy | $11 → $13 | $3.73 | +248.53% | 3 | Jun 9, 2025 | |
| HRTX Heron Therapeutics | Initiates: Buy | $6 | $1.98 | +203.80% | 2 | Jun 9, 2025 | |
| MIST Milestone Pharmaceuticals | Assumes: Buy | $5 | $1.62 | +209.60% | 2 | Jun 5, 2025 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $9 | $1.15 | +686.03% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.09 | +196.40% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.12 | +346.43% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.73 | +339.56% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.46 | +160.12% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.44 | +1,716.94% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $7.09 | +125.67% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.41 | +2,327.18% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $9.02 | +4,944.35% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $27.25 | +116.51% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $112.70 | +59.72% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.62 | +3,430.73% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $7.28 | +23.71% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.28 | +9.29% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $2.00 | +1,099,900.00% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $31.80 | -30.82% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $14.90 | +235.57% | 1 | Jul 12, 2018 |
MannKind
Jul 16, 2025
Assumes: Buy
Price Target: $9
Current: $3.82
Upside: +135.60%
ANI Pharmaceuticals
Jul 10, 2025
Initiates: Buy
Price Target: $84
Current: $67.75
Upside: +23.99%
Zevra Therapeutics
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $12.44
Upside: +109.00%
CorMedix
Jun 30, 2025
Initiates: Buy
Price Target: $20
Current: $11.00
Upside: +81.82%
Eupraxia Pharmaceuticals
Jun 26, 2025
Initiates: Buy
Price Target: $12
Current: $5.41
Upside: +121.83%
Connect Biopharma Holdings
Jun 12, 2025
Assumes: Buy
Price Target: $7
Current: $1.76
Upside: +297.70%
PolyPid
Jun 9, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $3.73
Upside: +248.53%
Heron Therapeutics
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.98
Upside: +203.80%
Milestone Pharmaceuticals
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.62
Upside: +209.60%
Cardiol Therapeutics
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.15
Upside: +686.03%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $7.09
Upside: +196.40%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.12
Upside: +346.43%
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.73
Upside: +339.56%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.46
Upside: +160.12%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.44
Upside: +1,716.94%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $7.09
Upside: +125.67%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.41
Upside: +2,327.18%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $9.02
Upside: +4,944.35%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $27.25
Upside: +116.51%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $112.70
Upside: +59.72%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.62
Upside: +3,430.73%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $7.28
Upside: +23.71%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.28
Upside: +9.29%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $2.00
Upside: +1,099,900.00%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $31.80
Upside: -30.82%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $14.90
Upside: +235.57%